James N. Topper - Insider Trading & Ownership

Location: 550 Hamilton Avenue, Suite 100, Palo Alto, CA
Summary: The estimated net worth of James N. Topper is at least $174M dollars as of August 13, 2025. James N. Topper is the Director of NewAmsterdam Pharma Co N.V. and owns shares of NewAmsterdam Pharma Co N.V. (NAMS) stock worth about $154M. James N. Topper is the Director, 10%+ Owner of Phathom Pharmaceuticals, Inc. and owns shares of Phathom Pharmaceuticals, Inc. (PHAT) stock worth about $19.6M. James N. Topper is the Director, 10%+ Owner of ANAPTYSBIO, INC and owns shares of ANAPTYSBIO, INC (ANAB) stock worth about $85.1K.
Signature: /s/ Steve R. Bailey, Attorney-in-Fact For James N. Topper
All Insider Reports: All Insider Reports

Ownership of James N. Topper

Symbol	Company	Relationship	Holdings Value	Past Year Net Change	Change %	Report Period
NAMS, NAMSW	NewAmsterdam Pharma Co N.V.	Director	$154M	+$358K	+0.23%	Aug 11, 2025
PHAT	Phathom Pharmaceuticals, Inc.	Director, 10%+ Owner	$19.6M	+$192K	+0.99%	Jun 3, 2025
ANAB	ANAPTYSBIO, INC	Director, 10%+ Owner	$85.1K			Jan 6, 2023
ALPN	ALPINE IMMUNE SCIENCES, INC.	Director	$0			May 18, 2024

Showing 1 to 4 of 4 entries

Insider Transactions Reported by James N. Topper:

Sym	Company	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership
NAMS	NewAmsterdam Pharma Co N.V.	Ordinary Shares	Purchase	+0.02%	$11.3K	23.98	+471	3.03M	8/11/2025	By Frazier Life Sciences X, L.P.
NAMS	NewAmsterdam Pharma Co N.V.	Ordinary Shares	Purchase	+0.04%	$23K	18.26	+1.26K	3.03M	6/25/2025	By Frazier Life Sciences X, L.P.
NAMS	NewAmsterdam Pharma Co N.V.	Ordinary Shares	Purchase	+0.08%	$46.5K	18.43	+2.52K	3.02M	6/24/2025	By Frazier Life Sciences X, L.P.
NAMS	NewAmsterdam Pharma Co N.V.	Ordinary Shares	Purchase	+0.28%	$167K	19.50	+8.58K	3.02M	6/16/2025	By Frazier Life Sciences X, L.P.
PHAT	Phathom Pharmaceuticals, Inc.	Common Stock	Award	+32.7%	$0	0.00	+10.5K	42.6K	6/3/2025	Direct
PHAT	Phathom Pharmaceuticals, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+17.5K	17.5K	6/3/2025	Direct
PHAT	Phathom Pharmaceuticals, Inc.	Common Stock	Purchase	+6.8%	$14.6K	3.86	+3.78K	59.4K	5/21/2025	By Frazier Life Sciences X, L.P.
PHAT	Phathom Pharmaceuticals, Inc.	Common Stock	Purchase	+12.8%	$20.9K	3.32	+6.3K	55.6K	5/14/2025	By Frazier Life Sciences X, L.P.
PHAT	Phathom Pharmaceuticals, Inc.	Common Stock	Purchase	+2.32%	$3.54K	3.16	+1.12K	49.3K	5/13/2025	By Frazier Life Sciences X, L.P.
PHAT	Phathom Pharmaceuticals, Inc.	Common Stock	Purchase	+35.4%	$38.3K	3.04	+12.6K	48.2K	5/12/2025	By Frazier Life Sciences X, L.P.
PHAT	Phathom Pharmaceuticals, Inc.	Common Stock	Purchase		$115K	3.22	+35.6K	35.6K	5/9/2025	By Frazier Life Sciences X, L.P.
NAMS	NewAmsterdam Pharma Co N.V.	Ordinary Shares	Purchase	+0.04%	$25.5K	22.49	+1.14K	3.01M	3/26/2025	By Frazier Life Sciences X, L.P.
NAMS	NewAmsterdam Pharma Co N.V.	Ordinary Shares	Purchase	+0.13%	$84.2K	21.02	+4.01K	3.01M	3/4/2025	By Frazier Life Sciences X, L.P.
PHAT	Phathom Pharmaceuticals, Inc.	Common Stock	Award	+48.6%	$0	0.00	+10.5K	32.1K	5/23/2024	Direct
PHAT	Phathom Pharmaceuticals, Inc.	Stock Option (Right to Buy)	Award	-50%	$0	0.00	-17.5K	17.5K	5/23/2024	Direct
ALPN	Alpine Immune Sciences, Inc.	Stock Option (Right to buy)	Disposed to Issuer	-100%	$0		-68.1K	0	5/20/2024	Direct
ALPN	Alpine Immune Sciences, Inc.	Common Stock	Disposition pursuant to a tender of shares in a change of control transaction	-100%	$0		-2.83M	0	5/18/2024	By Frazier Life Sciences VIII, L.P.
ALPN	Alpine Immune Sciences, Inc.	Common Stock	Sale		-$1.23K	64.57	-19	2.83M	4/25/2024	By: Frazier Life Sciences VIII, L.P.
ALPN	Alpine Immune Sciences, Inc.	Common Stock	Exercise of in-the-money or at-the-money derivative security	+73.7%	$1.2K	0.00^*	+1.2M	2.83M	4/25/2024	By: Frazier Life Sciences VIII, L.P.
ALPN	Alpine Immune Sciences, Inc.	Warrant (Right to Buy)	Exercise of in-the-money or at-the-money derivative security	-100%	$0	0.00^*	-1.2M	0	4/25/2024	By: Frazier Life Sciences VIII, L.P.
NAMS	NewAmsterdam Pharma Co N.V.	Ordinary Shares	Purchase	+0.28%	$181K	21.50	+8.43K	3.01M	3/26/2024	By Frazier Life Sciences X, L.P.
ALPN	Alpine Immune Sciences, Inc.	Stock Option (Right to buy)	Award		$0	0.00	+17.5K	17.5K	1/2/2024	Direct
ALPN	Alpine Immune Sciences, Inc.	Common Stock	Exercise of in-the-money or at-the-money derivative security	+9.79%	$1.85M	12.74	+145K	1.63M	12/11/2023	By: Frazier Life Sciences VIII, L.P.
ALPN	Alpine Immune Sciences, Inc.	Warrant (Right to Buy)	Exercise of in-the-money or at-the-money derivative security	-100%	$0	0.00^*	-145K	0	12/11/2023	Direct
PHAT	Phathom Pharmaceuticals, Inc.	Common Stock	Award	+71.5%	$0	0.00	+9K	21.6K	5/25/2023	Direct
PHAT	Phathom Pharmaceuticals, Inc.	Stock Option (Right to Buy)	Award		$0	0.00	+15K	15K	5/25/2023	Direct
ANAB	Anaptysbio, Inc	Stock Option (right to buy)	Award		$0	0.00	+10.6K	10.6K	1/6/2023	Direct
ANAB	Anaptysbio, Inc	Restricted Stock Unit	Award		$0	0.00	+3.9K	3.9K	1/6/2023	Direct
ALPN	Alpine Immune Sciences, Inc.	Stock Option (Right to buy)	Award		$0	0.00	+10K	10K	1/3/2023	Direct
PHAT	Phathom Pharmaceuticals, Inc.	Stock Option (Right to Buy	Award		$0	0.00	+20K	20K	9/22/2022	Direct
ANAB	Anaptysbio, Inc	Stock Option (right to buy)	Award		$0	0.00	+9.2K	9.2K	2/10/2022	Direct
ALPN	Alpine Immune Sciences, Inc.	Stock Option (Right to buy)	Award		$0	0.00	+10K	10K	1/3/2022	Direct

Previous1Next

Showing 1 to 32 of 32 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.